Table of Contents | --- | --- | --- | |------------|---------------------------------------------------------------------------------------------------------------------------|-------| | | | Page | | PART I | | | | Item 1. | Business | 8 | | Item 1A. | Risk Factors | 29 | | Item 1B. | Unresolved Staff Comments | 69 | | Item 1C. | Cybersecurity | 70 | | Item 2. | Properties | 72 | | Item 3. | Legal Proceedings | 72 | | Item 4. | Mine Safety Disclosures | 72 | | PART II | | | | Item 5. | Market for Registrant ...

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024. Conference & Webcast Details Date:Wednesday, March 6th, 2024Time:12:50 p.m. to 1:20 p.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the Bionano w ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Participa ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Particip ...

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ("Bionano") (NASDAQ:BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the "Buyer") (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 initially convertible by the Buyer into approximately 15.7 million shares ...

Now might be a good time to consider scooping up shares of penny stocks to buy on the dip. However, caution is essential, as penny stocks can be volatile and speculative. So to help reduce the risk to investors, I’ve chosen companies that seem to be on the safer side in terms of their fundamentals.So here are seven penny stocks to buy on the dip for February.BioNano Genomics (BNGO)Source: Dennis Diatel / Shutterstock.comBioNano Genomics (NASDAQ:BNGO) is a biotech stock that specializes in the analysis of ge ...

Over 2,100 registrants with attendees from 92 countriesAverage daily attendance of 574 32 oral presentations delivered across four consecutive days69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hallContent covered wide a range of research applications for OGM including hematologic malignancies, cell and gene therapy, and constitutional genetic diseasesOn-demand presentations from Symposium available for remainder of 2024 SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) - ...

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute and Scripps MD Anderson in La Jolla, California. The publication describes what could be the first study to use optical genome mapping (OGM) for the discovery of structural variants (SVs) that drive drug resistance and sensitivity in cancer.   ...

Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that is designed to measure the workflow's accuracy and clinical utility compared to classical cytogenetic methodsOGM data from 342 unique cases (419 datapoints) were analyzed and reported in the pre-print, including 123 samples from phase 1 of the study, which was reported in a pre-print publication in December 2022Phase 2 results show that OGM demonstrates comparable ...

Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial releaseThe Stratys instrument can enable up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips, accessible as they complete runs, without the need to batch multiple samples on a consumableData analysis for the Stratys system is powered by Stratys™ Compute, a high-performance workstation developed in collabo ...